Kohei Kumegawa

This study identifies DLX5 as a key driver of myofibroblastic carcinoma-associated fibroblasts (myCAFs) in breast cancer, showing its role in promoting tumor invasion through TGF-β signaling.

This study investigates how extrachromosomal DNA (ecDNA) copy numbers change during drug treatment, showing that resistant clones can actively reconfigure segregation behavior rather than relying on pre-existing clones.

The paper identifies hypoacetylation-defined enhancers in luminal breast cancer cells and links them to subtype-specific gene regulation and patient classification.

This study uses an integrated platform to show that ARID1A deficiency increases transcriptomic and epigenetic heterogeneity in cancer cells through stochastic and constrained chromatin changes.

This study identifies TIMELESS as a critical regulator of metastasis-initiating cell survival and reawakening in bone, with a metabolic inhibitor showing promise for therapeutic intervention.